By PR Newswire (Indevus) 9 February 2009: Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today that a National Institutes of Health (NIH)-sponsored clinical study found that participating women who received PRO 2000, the Company's candidate vaginal microbicide for HIV prevention, had an approximately 30% lower risk of acquiring HIV infection than women who received a placebo or no vaginal product.
-
Posted by
Mialy
-
Published:
2009-02-09